Literature DB >> 21418998

[Expression and clinical significance of Toll-like receptors in human renal carcinoma cell 786-0 and normal renal cell HK-2].

Hui Yu1, Shan-Shan Xu, Qin-Quan Cheng, Li-Mei He, Zhi Li.   

Abstract

OBJECTIVE: To investigate the expression of toll-like receptors (TLR1-TLR10) in human renal carcinoma cell 786-0 and normal renal cell HK-2 and discuss the significance of TLRs in the development of renal carcinoma.
METHODS: Human renal carcinoma cell 786-0 (experimental group) and normal renal cell HK-2 (control group) were cultured. The expression of TLR1-TLR10 was detected by real-time fluorogenic quantitative PCR (FQ-PCR).
RESULTS: The FQ-PCR analysis demonstrated that 786-0 cell line and HK-2 cell line expressed TLR1-TLR6 and TLR8-TLR10 mRNA. Yet neither had an expression of TLR7. Moreover, the expression levels of TLR1, TLR2, TLR4, TLR5, TLR6, TLR8 and TLR10 in the experimental group were significantly higher than those in HK-2 cell line [(4.40 ± 0.19) × 10(-2), (1.77 ± 0.24) × 10(-2), (5.03 ± 0.62) × 10(-2), (3.93 ± 0.86) × 10(-2), (6.11 ± 0.48) × 10(-2), (1.89 ± 0.47) × 10(-2), (2.84 ± 0.57) × 10(-2) vs (0.84 ± 0.27) × 10(-2), (0.40 ± 0.04) × 10(-2), (0.95 ± 0.73) × 10(-2), (0.56 ± 0.25) × 10(-2), (0.49 ± 0.16) × 10(-2), (0.20 ± 0.07) × 10(-2), (0.27 ± 0.08) × 10(-2), P < 0.01]. There was no significant change in the expressions of TLR3 and TLR9 between 786-0 and HK-2 cell line (P > 0.05).
CONCLUSION: The expressions of TLR1, TLR2, TLR4, TLR5, TLR6, TLR8 and TLR10 are significantly higher in 786-0 cell line than those in HK-2 cell line. They may play key roles in the development of renal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21418998

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  1 in total

1.  Novel sequence variants in the TLR6 gene associated with advanced breast cancer risk in the Saudi Arabian population.

Authors:  Abdelhabib Semlali; Mikhlid Almutairi; Mahmoud Rouabhia; Narasimha Reddy Parine; Abdullah Al Amri; Nouf S Al-Numair; Yousef M Hawsawi; Mohammad Saud Alanazi
Journal:  PLoS One       Date:  2018-11-02       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.